Lipella pharmaceuticals announces delisting from nasdaq capital market

Pittsburgh, june 20, 2025 (globe newswire) -- lipella pharmaceuticals inc. (otc: lipo) (“lipella” or the “company”), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet needs, today announced that the nasdaq hearings panel has determined to delist the company's common stock from the nasdaq capital market. trading in the common stock was suspended at the open of business today.
LIPO Ratings Summary
LIPO Quant Ranking